<DOC>
	<DOCNO>NCT01652872</DOCNO>
	<brief_summary>A phase 3 , multicenter , randomize , double-blind , parallel group study . Anemic subject chronic kidney disease dialysis randomize 1:1 1 2 dosing strategy evaluate proportion subject receive least one red blood cell transfusion . In Hb-based titration group , darbepoetin alfa dos titrate maintain hemoglobin ( Hb ) ≥ 10.0 g/dL . In fixed dose group , subject receive fix dose darbepoetin alfa . Treatment group , darbepoetin alfa dos , protocol specify Hb concentration blind . Subjects follow approximately 2 year date randomization .</brief_summary>
	<brief_title>Strategies Using Darbepoetin Alfa Avoid Transfusions Chronic Kidney Disease</brief_title>
	<detailed_description>The study phase 3 , multicenter , randomize , double-blind , parallel group study design describe benefit potential risk new treatment strategy use fix dose darbepoetin alfa subject chronic kidney disease dialysis . Anemic subject without recent use erythropoiesis stimulate agent ( ESA ) randomly allocate 1:1 treatment fix dose darbepoetin alfa treatment darbepoetin alfa use hemoglobin ( Hb ) -based titration strategy , conventional dosing strategy . In Hb-based titration group , darbepoetin alfa dos titrate maintain hemoglobin ( Hb ) ≥ 10.0 g/dL . This study aim estimate incidence red blood cell ( RBC ) transfusion ( administer deem clinically necessary ) group difference incidence RBC transfusion 2 group . In addition , multiple aspect , cumulative darbepoetin alfa dose , total number unit transfusion , Hb concentration , Hb-related parameter ( eg , Hb variability , excursion , rate change ) , adverse ( eg , cardiovascular ) event , also consider order determine prefer dose regimen . Treatment group , darbepoetin alfa dos , protocol specify Hb concentration blind investigator , subject study team . Subjects follow approximately 2 year date randomization .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Key Hb concentration &lt; 10.0 g/dL Estimated glomerular filtration rate &lt; 45.0 mL/min/1.73m2 Transferrin saturation ( TSAT ) ≥ 20 % ferritin ≥ 100 ng/mL Clinically stable investigator Key Received erythropoiesis stimulate agent ( ESAs ) within 4 week screen Received red blood cell transfusion within 8 week screen Received intravenous iron change oral iron therapy within 4 week screen Uncontrolled hypertension , define study , mean systolic blood pressure &gt; 140 mmHg screen visit , mean systolic blood pressure &gt; /= 160 mmHg screen visit , mean diastolic blood pressure &gt; /= 90 mmHg screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>kidney disease</keyword>
	<keyword>renal failure</keyword>
</DOC>